Predictors of kidney disease progression in diabetes and precision medicine: Something old, something new, and something borrowed

George Vasquez-Rios; Steven G. Coca

doi:10.1681/ASN.2021070945

Predictors of kidney disease progression in diabetes and precision medicine: Something old, something new, and something borrowed

George Vasquez-Rios
, Steven G. Coca

Research output: Contribution to journal › Editorial

4 Scopus citations

Original language	English
Pages (from-to)	2108-2111
Number of pages	4
Journal	Journal of the American Society of Nephrology
Volume	32
Issue number	9
DOIs	https://doi.org/10.1681/ASN.2021070945
State	Published - Sep 2021

Access to Document

10.1681/ASN.2021070945

Cite this

@article{9a304cbacc1a40baa425ec092f0e4ec1,

title = "Predictors of kidney disease progression in diabetes and precision medicine: Something old, something new, and something borrowed",

author = "George Vasquez-Rios and Coca, \{Steven G.\}",

note = "Funding Information: In the past 3 years, S.G. Coca reports receiving fees for advisory boards or steering committee roles for Akebia, Bayer, Boehringer-Ingelheim, CHF Solutions, ProKidney, Quark, Reprieve Cardiovascular, Renalytix, Takeda, and Vifor; reports owning equity in pulseData and Renalytix; reports having patents and inventions with Renalytix; reports receivingsalary and research support from the NIH (grants U01DK106962, R01DK115562, R01HL85757, R01DK112258, U01OH011326, and R01DK126477), ProKidney, Renalytix, the Renal Research",

year = "2021",

month = sep,

doi = "10.1681/ASN.2021070945",

language = "English",

volume = "32",

pages = "2108--2111",

journal = "Journal of the American Society of Nephrology",

issn = "1046-6673",

publisher = "Wolters Kluwer Health",

number = "9",

}

TY - JOUR

T1 - Predictors of kidney disease progression in diabetes and precision medicine

T2 - Something old, something new, and something borrowed

AU - Vasquez-Rios, George

AU - Coca, Steven G.

N1 - Funding Information: In the past 3 years, S.G. Coca reports receiving fees for advisory boards or steering committee roles for Akebia, Bayer, Boehringer-Ingelheim, CHF Solutions, ProKidney, Quark, Reprieve Cardiovascular, Renalytix, Takeda, and Vifor; reports owning equity in pulseData and Renalytix; reports having patents and inventions with Renalytix; reports receivingsalary and research support from the NIH (grants U01DK106962, R01DK115562, R01HL85757, R01DK112258, U01OH011326, and R01DK126477), ProKidney, Renalytix, the Renal Research

PY - 2021/9

Y1 - 2021/9

UR - https://www.scopus.com/pages/publications/85114153984

U2 - 10.1681/ASN.2021070945

DO - 10.1681/ASN.2021070945

M3 - Editorial

C2 - 34465605

AN - SCOPUS:85114153984

SN - 1046-6673

VL - 32

SP - 2108

EP - 2111

JO - Journal of the American Society of Nephrology

JF - Journal of the American Society of Nephrology

IS - 9

ER -